GIBBSTOWN, NJ /BUSINESS WIRE/ -- EMD Chemicals Inc. announced the extension of its existing strategic alliance with Nano-Terra Inc., a leading nanotechnology co-development company. EMD Chemicals is a U.S. subsidiary of Merck KGaA in Darmstadt, Germany.
The original agreement between the companies, announced in February 2007, was to develop innovative, nanotechnology-based products and solutions based on Merck KGaA's materials. After successfully meeting initial development milestones, the new agreement will focus on specific application development for Merck customers and moving the technical capabilities into the marketplace for commercialization.
Under the new agreement, which extends the partnership through 2011, Nano-Terra will develop novel application techniques for existing Merck materials which are designed to address market opportunities where smaller (micron and nanometer) feature sizes are required for certain printable electronics components. The Merck fabrication processes will be based on Nano-Terra's proprietary soft lithography technology, invented and pioneered by Professor George Whitesides of Harvard University, a co-founder of Nano-Terra, and the partners will share commercialization rights on a global basis. Terms of the agreement were not disclosed.
The new development work will be done at Nano-Terra's lab facilities in Cambridge, MA, with close cooperation of a Merck scientific team and by the new Cambridge Innovation Laboratory of EMD Chemicals.
Dr. Thomas Geelhaar, Chief Technology Officer Chemicals of Merck KGaA, said, "We were very pleased by the progress made in the initial stages of our relationship with Nano-Terra. We look forward to our continued collaboration with Professor Whitesides and his team, and to building on these developments to create specific products that we believe will provide significant benefits to our customers."
"Through its embrace of innovative technologies and applications, Merck continues to underscore its commitment as a pioneer in research and development," said Dr. Carmichael Roberts, Vice Chairman of Nano-Terra. "We are delighted to extend our working relationship with them and to enhance their exploration of how to best optimize materials to improve products and processes for its customers."
In 2006, Merck KGaA bestowed on Professor Whitesides the prestigious Emanuel Merck Lectureship prize.
About Nano-Terra
Nano-Terra Inc. is a privately-held research and development company that has field-exclusive licenses to more than 50 patents on work done by co-founder Dr. George Whitesides at the renowned Whitesides Lab at Harvard University, where he is the Woodford L. and Ann A. Flowers University Professor. He is the recipient of the 2007 Priestley Medal.
The company leverages its intellectual property through co-development and other agreements with Fortune 500 industrial and manufacturing companies and the U.S. government. Nano-Terra's scientific methods can be used to fabricate advanced materials and devices that enhance existing products or create entirely new products in a broad range of areas. These include smart materials and surfaces; flexible electronics, such as displays and electronic packaging; fuel cells, batteries, and solar power devices; sensors; industrial products and processes; and a wide range of consumer goods.
About EMD
EMD Chemicals Inc. represents the North American chemical sector of Merck KGaA, Darmstadt, Germany. As an international organization with 1100 employees and revenues of more than $350 million, EMD Chemicals focuses on specialty chemicals for pharmaceutical, biotech, cosmetic, agricultural, automotive, plastics, electronics, and other industrial applications.
About Merck
Merck KGaA is a global pharmaceutical and chemical company with total revenues of € 7.1 billion in 2007, a history that began in 1668, and a future shaped by 31,946 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917, the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.